



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 2/14/05

Signature: 

(Susan Lanney)

Docket No.: MDSP-P01-002  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
McFadden *et al.*

Application No.: 10/090,440

Confirmation No.: 3416

Filed: March 4, 2002

Art Unit: 1642

For: METHODS AND REAGENTS FOR  
REGULATING APOPTOSIS

Examiner: M. Yu

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


9648996\_1

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. MDSP-P01-002. A duplicate copy of this paper is enclosed.

Dated: February 10, 2005

Respectfully submitted,

By  \_\_\_\_\_  
Yu Lu, Patent Agent  
Registration No.: 50,306  
ROPES & GRAY LLP  
One International Place  
Boston, Massachusetts 02110-2624  
(617) 951-7000  
(617) 951-7050 (Fax)  
Agent For Applicant



PTO/SB/C8a/b (08-03)

Approved for use through 07/31/2006. OMB C651-C331

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/090440
				Filing Date	March 4, 2002
				First Named Inventor	Grant McFadden
				Art Unit	1642
				Examiner Name	M. Yu
Sheet	1	of	2	Attorney Docket Number	MDSP-P01-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US-5,283,173	02-01-1994	Fields et al.	
	AB	US-5,580,736	12-03-1996	Brent et al.	
	AC	US-5,610,015	03-11-1997	Wickens et al.	
	AD	US-5,695,941	12-09-1997	Brent et al.	
	AE	US-5,955,280	09-21-1999	Vidal et al.	
	AF	US-5,965,368	10-12-1999	Vidal et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CA	Barry, M., et al., "The Myxoma Virus M-T4 Gene Encodes a Novel RDEL-Containing Protein that is Retained within the Endoplasmic Reticulum and is Important for the Productive Infection of Lymphocytes," <i>Virology</i> , 239:360-377 (1997).		
	CB	Bartel, et al., "Elimination of False Positives That Arise in Using the Two-Hybrid System," <i>BioTechniques</i> , 14(6):920-924 (1993).		
	CC	Cheng, E.H.Y., et al., "Bax-independent inhibition of apoptosis by Bcl-xL," <i>Nature</i> , 379:554-556 (1996).		
	CD	Chittenden, T., et al., "A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions," <i>EMBO J.</i> 14:5589-5596 (1995).		
	CE	Graham, K.A., et al., "Myxoma Virus M11L ORF Encodes a Protein for Which Cell Surface Localization Is Critical in Manifestation of Viral Virulence," <i>Virology</i> , 191:112-124 (1992).		
	CF	Iwabuchi, K., et al., "Use of the two-hybrid system to identify the domain of p53 involved in oligomerization," <i>Oncogene</i> , 8:1693-1696 (1993).		
	CG	Macen, J.L., et al., "Expression of the Myxoma Virus Tumor Necrosis Factor Receptor Homologue (T2) and M11L Genes is Required to Prevent Virus-Induced Apoptosis in Infected Rabbit T Lymphocytes," <i>Virology</i> , 218:232-237 (1996).		
	CH	Madura, K., et al., "N-recognition/Ubc2 Interactions in the N-end Rule Pathway," <i>J. Biol. Chem.</i> , 268:12046-54 (1993).		
	CI	McFadden, G. and Barry, M., "How Poxviruses Oppose Apoptosis," <i>Semin. Virol.</i> , 8:429-442 (1998).		
	CJ	Mossman, K., et al., "Disruption of M-T5, a Novel Myxoma Virus Gene Member of the Poxvirus Host Range Superfamily, Results in Dramatic Attenuation of Myxomatosis in Infected European Rabbits," <i>J. Virol.</i> , 70(7):4394-4410 (1996).		
Examiner Signature				Date Considered

9648998\_1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/090440
				Filing Date	March 4, 2002
				First Named Inventor	Grant McFadden
				Art Unit	1642
				Examiner Name	M. Yu
Sheet	2	of	2	Attorney Docket Number	MDSP-P01-002

CK	Muchmore, S.W., et al., "X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death," Nature, 381:335-341 (1996).	
CL	Oltvai, Z.N. and Korsmeyer, S.J., "Checkpoints of Dueling Dimers Foil Death Wishes," Cell, 79:189-192 (1994).	
CM	Opgenorth, A., et al., "Deletion Analysis of Two Tandemly Arranged Virulence Genes in Myxoma Virus, M11L and Myxoma Growth Factor," J. Virol., 66(8):4720-4731 (1992).	
CN	Yin, X.M., et al., "BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax," Nature, 369:321-323 (1994).	
CO	Zervos, A.S., et al., "Mxi1, a Protein That Specifically Interacts with Max to Bind Myc-Max Recognition Sites," Cell, 72:223-232 (1993).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/82 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/090440


Attorney Docket No.: MDSP-P01-002

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on February 10, 2005  
Date

  
\_\_\_\_\_  
Signature

Susan Lanney

\_\_\_\_\_  
Typed or printed name of person signing Certificate

\_\_\_\_\_  
Registration Number, if applicable

\_\_\_\_\_  
(617) 951-7000  
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (21 References) (2 pages)  
Information Disclosure Statement  
This Postcard Receipt